Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:33 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Cancer Clear all

Conditions: Invasive Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
Interventions: Propranolol; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sarcoma
Interventions: doxorubicin hydrochloride, ifosfamide and mesna, hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Mark Dewhirst; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cancer Survivor, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Interventions: Afimoxifene, Core Biopsy, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia, HPV Related Disease
Interventions: Artesunate vaginal insert, Placebo vaginal insert; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 25 Years to 100 Years · Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Fort Myers, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more

Conditions: Lung Cancer
Interventions: Low-dose CT scan; Device
Lead sponsor: Guardant Health, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 12,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 125
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Anaheim, California + 105 more

Conditions: Liver Cancer
Interventions: Not listed
Lead sponsor: Pathfinder Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: cisplatin, gemcitabine hydrochloride, paclitaxel; Drug
Lead sponsor: European Organisation for Research and Treatment of Cancer - EORTC; Network
Eligibility: 18 Years and older
Enrollment: 608 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 58
States / cities: Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 37 more

Conditions: Head and Neck Cancer
Interventions: Acupuncture-Like Transcutaneous Electrical Stimulation (ALTENS); Radiation
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Benign Prostatic Hyperplasia
Interventions: Urolift; Device
Lead sponsor: Northwell Health; Other
Eligibility: 50 Years to 99 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Syosset, New York

Conditions: HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Interventions: DS-8201a, T-DM1; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 126
States / cities: Anaheim, California • Baldwin Park, California • Bellflower, California + 94 more

Conditions: Invasive Breast Cancer
Interventions: Proton Radiation; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC), Muscle Invasive Bladder Cancer Urothelial Carcinoma, Cystectomy
Interventions: Intravenous fluids, ERAS; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Bladder Cancer
Interventions: Vicinium; Biological
Lead sponsor: Sesen Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more

Conditions: Bladder Cancer
Interventions: Erlotinib, Radical Cystectomy; Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions: gefitinib; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 95
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more

Conditions: Invasive Thymoma and Thymic Carcinoma, Recurrent Thymoma and Thymic Carcinoma, Stage III Thymoma, Stage IVA Thymoma, Stage IVB Thymoma
Interventions: saracatinib; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 2
States / cities: Stanford, California • Indianapolis, Indiana

Conditions: Breast Cancer
Interventions: Curcumin; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Urothelial Carcinoma
Interventions: retifanlimab, epacadostat, INCAGN02385, INCAGN02390; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Iowa City, Iowa • Cincinnati, Ohio • Columbus, Ohio + 1 more

Conditions: Bladder Cancer, Recurrent Bladder Cancer, FGFR3 Gene Mutation
Interventions: Erdafitinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
Interventions: Sacituzumab Govitecan, Pembrolizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 239 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts

Conditions: Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations, FGFR3 Gene Alteration, FGFR3 Gene Mutation, FGFR3 Gene Fusions
Interventions: TYRA-300 60mg, TYRA-300 50mg, TYRA-300 Dose 70 mg; Drug
Lead sponsor: Tyra Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 36
States / cities: Homewood, Alabama • Little Rock, Arkansas • Murrieta, California + 31 more

Conditions: Clear Cell Renal Cell Carcinoma
Interventions: 89Zr-DFO-girentuximab; Diagnostic Test
Lead sponsor: Telix Pharmaceuticals (Innovations) Pty Limited; Industry
Eligibility: 18 Years to 99 Years
U.S. locations: 22
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 19 more

Conditions: Pharmacokinetics
Interventions: BCG in Combination with N-803, N-803 alone; Biological · Drug
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Los Angeles, California • Miami, Florida • Omaha, Nebraska + 3 more

Conditions: Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Interventions: Agent Affecting Integumentary System, Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment, Quality-of-Life Assessment, Questionnaire Administration; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients

MRI Sarcoma Non Invasive Thermometry

Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast

Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

Screening for High Frequency Malignant Disease

Feasibility of a Minimally Invasive Image-Guided Surgery System for Hepatic Procedures

Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer

Study of Non-invasive Acupuncture-like Transcutaneous Electrical Nerve Stimulation (Altens) to Help Alleviate Xerostomia After Radiation Therapy for Cancers of the Head and Neck

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

Proton Radiation Therapy for Invasive Breast Cancer Following Mastectomy

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG

Erlotinib Before and After Surgery in Treating Patients With Muscle-Invasive Bladder Cancer

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic Cancer

A "Window Trial" on Curcumin for Invasive Breast Cancer Primary Tumors

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Sacituzumab Govitecan In TNBC

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

89Zr-DFO-girentuximab Expanded Access Program (EAP)

PK Sub-Study of QUILT-3.032 (CA ALT-803-01-16) and of QUILT-2.005 (CA ALT-803-01-14)

Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer